2017年 Tatsuzawa M, Ogawa R, Kinjo N, Kim S, Shimizu F, Sakamoto Y, Shimojima K, Echizen H, Miyazaki A: Consequences of different corticosteroids on serum potassium and prostate-specific antigen in patients receiving abiraterone for castration-resistant prostate cancer: a retrospective observational study. Clin Med Insights Oncol. 2017;11:1-7. [PMID: 29118587]
Takahashi M, Echizen H: Authors' reply to Dr. Bailey's commentary: Predicting clinical relevance of grapefruit-drug interactions: A complicated process. J Clin Pharm Ther. 2017;42:800-1. [PMID: 28695578]
Ogawa Y, Takei H, Ogawa R, Mihara K: Safety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studies. J Pharm Health Care Sci. 2017;3:18. [PMID: 28702209]
Nakayama H, Echizen H, Ogawa R, Akabane A, Kato T, Orii T: Induration at injection or infusion site may reduce bioavailability of parenteral phenobarbital administration. Ther Drug Monit. 2017;39:297-302. [PMID: 28328763]
Aonuma K, Shiga T, Atarashi H, Doki K, Echizen H, Hagiwara N, Hasegawa J, Hayashi H, Hirao K, Ichida F, Ikeda T, Maeda Y, Matsumoto N, Sakaeda T, Shimizu W, Sugawara M, Totsuka K, Tsuchisita Y, Ueno K, Watanabe E, Hashiguchi M, Hirata S, Kasai H, Matsumoto Y, Nogami A, Sekiguchi Y, Shinohara T, sugiyama A, Sumitomo N, Suzuki A, Takahashi N, Yukawa E, Homma M, Horie M, Inoue H, Ito H, Miura T, Ohe T, Shinozaki K, Tanaka K; Japanese Circulation Society and the Japanese Society of Therapeutic Drug Monitoring Joint Working Group: Guidelines for therapeutic drug monitoring of cardiovascular drugs clinical use of blood drug concentration monitoring (JCS 2015) -digest version. Circ J. 2017;81:581-612. [PMID: 28302953]
Shibata S, Takahashi H, Baba A, Takeshita K, Atsuda K, Matsubara H, Echizen H: Delayed de-induction of CYP2C9 activity compared to CYP3A after discontinuation of rifampicin: Report of two cases. Int J Clin Pharmacol Ther. 2017;55:449-52. [PMID: 28157069]
Funahashi K, Koyano S, Echizen H, Matsubara T: Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritis. Mod Rheumatol. 2017;27:271-7. [PMID: 27416107]
Takahashi H, Ohara M, Shibata S, Lee MT, Cavallari LH, Nutescu EA, Scordo MG, Pengo V, Padrini R, Atsuda K Matsubara H, Chen YT, Echizen H: Correlations between the enantio- and regio-selective metabolisms of warfarin. Pharmaogenomics. 2017;18:133-42. [PMID: 27995809]
Shimizu T, Momose Y, Ogawa R, Takahashi M, Echizen H: Impact of pharmacists’ audit on improving the quality of prescription of dabigatran etexilate methanesulfonate: a retrospective study. J Pharm Health Care Sci. 2017;3:4. [PMID: 28116115]
2016年 Tatsuzawa M, Ogawa R, Ohkubo A, Shimojima K, Maeda K, Echizen H, Miyazaki A: Influence of proton pump inhibitors and histamine H2 receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing hemodialysis: a retrospective medical chart review. J Pharm Health Care Sci. 2016;2:34. [PMID: 27895933]
Hirai T, Kimura T, Echizen H: Modeling and simulation for estimating the influence of renal dysfunction on hypouricemic effect of febuxostat in hyperuricemic patients due to overproduction or underexcretion of uric acid. Biol Pharm Bull. 2016;39:1013-21. [PMID: 27251504]
Nakayama H, Usuki K, Echizen H, Ogawa R, Orii T: Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Biol Pharm Bull. 2016;39:285-8. [PMID: 26830487]
Ohgushi A, Ohtani T, Nakayama N, Asai S, Ishii Y, Namiki A, Akazawa M, Echizen H: Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study. J Pharm Health Care Sci. 2016;2:2. [PMID: 26819747]
Echizen H: The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55:409-18. [PMID: 26369775]
2015年 高橋雅弘、緒方宏泰:OTC医薬品の有効性および安全性の科学的根拠に関するメタ解析:OTC緩下剤の評価.アプライド・セラピューティクス.2015;6:41-53.
Takahashi M, Onozawa S, Ogawa R, Uesawa Y, Echizen H: Predictive performance of three practical approaches for grapefruit juice-induced 2-fold or greater increases in AUC of concomitantly administered drugs. J Clin Pharm Ther. 2015;40:91-7. [PMID: 25365914]
2014年 Ogawa R, Stachnik J, Echizen H: Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally). Clin Pharmacokinet. 2014;53:1083-114. [PMID: 25248847]
Nobuoka Y, Ogawa R, Echizen H: Simultaneous determination of N1-methylnicotinamide, L-carnitine, and creatinine in human plasma and urine by liquid chromatography with mass spectrometry for assessing the activities of multiple renal cationic transporters. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;967:240-4. [PMID: 25129409]
Shibata S, Takahashi H, Ono N, Wada N, Kubo H, Shinozaki K, Saito H, Inamoto N, Machida M, Atsuda K, Echizen H: Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis. J Clin Pharm Ther. 2014;39:181-5. [PMID: 24405193]
2013年 小川竜一:心房細動の薬物治療管理.アプライド・セラピューティクス.2013;4:35-46.
Ogawa R, Kobayashi S, Sasaki Y, Makimura M, Echizen H: Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection. Int J Clin Pharmacol Ther. 2013;51:357-66. [PMID: 23458228]
Ogawa R, Stachnik J, Echizen H: Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously). Clin Pharmacokinet. 2013;52:169-85. [PMID: 23344981]
Mae H, Ooi J, Takahashi S, Kato S, Kawakita T, Ebihara Y, Tsuji K, Nagamura F, Echizen H, Tojo A: Acute kidney injury after myeloablative cord blood transplantation in adults: the efficacy of strict monitoring of vancomycin serum trough concentrations. Transpl Infect Dis. 2013;15:181-6. [PMID: 23279721]
2012年 Ichimura Y, Takahashi H, Lee MT, Shiomi M, Mihara K, Morita T, Chen YT, Echizen H: Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy. Clin Pharmacokinet. 2012;51:799-808. [PMID: 23018470]
白吉紘幸、松田絹代、西郷織江、中島博史、大西幸江、原田好子、西羅輝雄、櫻井順子、一瀬直子、奥野滋子、鶴丸昌彦、佐瀬一洋、越前宏俊:3. オピオイドレスキューの患者自己管理実態と自己管理実施に対する医療従事者の意識調査.日本病院薬剤師会雑誌.2012;48;329-35.
2011年 Ogawa R, Echizen H: Clinically significant drug interactions with antacids: an update. Drugs. 2011;71:1839-64. [PMID: 21942976]
2010年 Ogawa R, Echizen H: Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49:509-33. [PMID: 20608754]
Ogawa R, Kishi R, Takagi A, Sakaue I, Takahashi H, Matsumoto N, Masuhara K, Nakazawa K, Kobayashi S, Miyake F, Echizen H: A novel microsatellite polymorphism of sodium channel beta1-subunit gene (SCN1B) may underlie abnormal cardiac excitation manifested by coved-type ST-elevation compatible with Brugada syndrome in Japanese. Int J Clin Pharmacol Ther. 2010;48:109-19. [PMID: 20137763]
2009年 Nakayama H, Echizen H, Gomi T, Shibuya Y, Nakamura Y, Nakano K, Arashi H, Ohnishi S, Tanaka M, Orii T: Urinary lipocalin-type prostaglandin D synthase: a potential marker for early gentamicin-induced renal damage? Ther Drug Monit. 2009;32:126-30. [PMID: 19125150]
2008年 神山尚子、小川竜一、浜田寛子、大野哲郎、浅野竜太、梅村純、吉田久博:冠動脈造影及び冠動脈形成術後の造影剤腎症に対するN-アセチルシステインの予防効果の検討.薬学雑誌.2008;128:1333-9.[PMID: 18758148]
Dohiguchi Y, Shiba S, Masuda Y, Kurihara Y, Hasegawa S, Echizen H: Bioequivalence studies between 0.5, 1, and 5 mg warfarin potassium tablets of new formula and those of standard formula. Jpn Pharmacol Ther. 2008;36:401-9.
Nakayama H, Echizen H, Tanaka M, Sato M, Orii T: Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks. Ther Drug Monit. 2008;30:103-7. [PMID: 18223471]
2007年 Abe Y, Nanri Y, Oto H, Kitabayashi T, Watanabe S, Odajima Y, Itabashi K, Takahashi H, Echizen H: Effect of low-dose macrolide antibiotics on theophylline disposition in pediatric patients. 日本小児呼吸器疾患学会誌. 2007;18:7-13.
Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H: Meta-analysis of risk of malignancy with use of immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007;41:21-8. [PMID: 17200426]
Shibuya M, Okamoto H, Nozawa T, Utsumi J, Reddy VN, Echizen H, Tanaka Y, Iwata T: Proteomic and transcriptomic analyses of retinal pigment epithelial cells exposed to REF-1/TFPI-2. Invest Ophtalmol Vis Sci. 2007;48:516-21. [PMID: 17251444]
佐藤(朝増)沙智子、三田充男、小川竜一、井坂眞人、齋藤政樹:経皮的冠動脈ステント留置術施行後の再狭窄に影響を及ぼす臨床的因子の検討.薬学雑誌.2007;127:1309-15.[PMID: 17666885]
2006年 田島満子、真鍋公二、小笠原芳宏、越前宏俊:ラロキシフェンによる閉経後骨粗鬆症に対する治療効果−滝山病院における1年間の調査−.日病薬誌.2006;42:233-6.
田島満子、両角 智、小笠原芳宏、越前宏俊:血液透析患者の高ホモシステイン血症の改善を目的とする葉酸サプリメント服用の試み.日病薬誌.2006;42:511-6.
Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie DM, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H: Different contribution of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasian and African Americans. Pharmacogenet Genomics. 2006;16:101-10. [PMID: 16424822]
Ogawa R, Kishi R, Mihara K, Takahashi H, Takagi A, Matsumoto N, Masuhara K, Nakazawa K, Miyake F, Kobayashi S, Echizen H: Population Pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias. J Clin Pharmacol. 2006;46:59-68. [PMID: 16397285]
2005年 Ohnishi A, Murakami S, Akizuki S, Mochizuki J, Echizen H, Takagi T: In vivo metabolic activity and genetic polymorphism of CYP2C19 and CYP3A in chronic liver disease. J Clin Pharmacol. 2005;45:1221-9. [PMID: 16239354]
2004年 Ohno K, Masunaga Y, Ogawa R, Hashiguchi M, Ogata H: A systematic review of the clinical effectiveness of azathioprine in patients with ulcerative colitis. Yakugaku Zasshi. 2004;124:555-60. [PMID: 15297725]
岸 良示、中沢 潔、小川竜一、松本直樹、高木明彦、長田圭三、桜井庸晴、宮津 修、渡邉義之、松田央郎、村野浩太郎、麻生健太郎、原田智雄、三宅良彦:多数の突然死の家族歴を有する特発性肥大型心筋症とBrugada症候群の合併家系.心臓.2004;36 Suppl 3:24-8.
Takahashi H, Wilkinson GR, Padrini R, Echizen H: CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin Pharmacol Ther. 2004;75:376-80. [PMID: 15116049]
Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K, Echizen H: 5´-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in Caucasian and Japanese patients. Blood. 2004;103:3055-7. [PMID: 15070684]
Yamaguchi T, Ida T, Hiraga M, Oishi K, Uchida MK, Echizen H: Effects of angiotensin II receptor blockers, angiotensin converting enzyme Inhibitors, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase inhibitors, amlodipine and epalrestat on cultured basilar artery smooth muscle cell proliferation. J Pharm Soc Jpn. 2004;124:159-63. [PMID: 15049134]
Yamaguchi T, Ida T, Kobayashi T, Hiraga M, Oishi K, Uchida MK, Echizen H: Alterations of antiproliferative effects of serum obtained from patients with acute cerebral infarction treated with a radical scavenger, edaravone, with or without amlodipine using an in vitro cultured basilar artery smooth muscle cells. J Pharm Soc Jpn. 2004;124,25-30. [PMID: 14768352]
2003年 岸 良示、中沢 潔、桜井庸晴、小川竜一:Brugada症候群におけるピルジカイニド誘発ST上昇の程度と臨床像の関係.心電図.2003;23 Suppl 4:S4-18-S4-20.
Yamaguchi T, Oishi K, Uchida M, Echzien H: Edaravone, a radical scavenger, may enhance or produce antiproliferative effects of fluvastatin, amlodipine, ozagrel, GF109203 and Y27632 on cultured basilar artery smooth muscle cells. Biol Pharm Bull. 2003;26:1706-10. [PMID: 14646175]
Ohno K, Miyazawa S, Hashiguchi M, Unemoto T, Itoh A, Echizen H, Rikihisa T, Ogata H, Murata M: Establishing a comprehensive questionnaire for detecting drug-induced extrapyramidal symptoms. Yakugaku Zasshi. 2003;123:881-6. [PMID: 14577334]
Saruwatari J, Nakagawa K, Shindo J, Nachi S, Echizen H, Ishizaki T: The in-vivo effects of sho-saiko-to, a traditional Chinese herbal medicine, on two cytochrome P450 enzymes (1A2 and 3A) and xanthine oxidase in man. J Pharm Pharmacol. 2003;55:1553-9. [PMID: 14713367]
Takahashi H, Echizen H: Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmcogenomics J. 2003;3:202-14. [PMID: 12931134]
Shibuya M, Echizen H, Kubo S, Tamura N, Suzuki K, Ushiama H, Ohnishi A: Reduced urinary 6beta-hydroxycortisol to cortisol ratios in patients with liver cirrhosis. Hepatology Res. 2003;26:28-33. [PMID: 12787801]
Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H: Population differences in (S)-warfarin metabolism between CYP2C9 genotype-matched Caucasians and Japanese patients. Clin Pharmacol Ther. 2003;73:253-63. [PMID: 12621390]
2002年 宇治田和子、大野恵子、橋口正行、越前宏俊、力久忠昭、緒方宏泰:市中病院における高脂血症に対する薬物治療の現状と問題点の検討.薬学雑誌.2002;122:499-506.[PMID: 12136647]
Kanamori M, Takahashi H, Echizen H: Developmental changes in the liver weight-and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children. Int J Clin Pharmacol Ther. 2002;40:485-92. [PMID: 12698985]
Ohkawa K, Hashiguchi M, Ohno K, Kiuchi C, Takahashi S, Kondo S, Echizen H, Ogata H: Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther. 2002;72:220-6. [PMID: 12189369]
Ushiama H, Echizen H, Nachi S, Ohnishi A: Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther. 2002;72:33-43. [PMID: 12152002]
Takahashi M, Echizen H, Takahashi K, Shimada S, Aoyama N, Izumi T: Extremely prolonged elimination of cibenzoline at toxic plasma concentrations in patients with renal impairments. Ther Drug Monit. 2002;24:492-6. [PMID: 12142632]
Kadota K, Kamata K, Kobayashi Y, Kagaya H, Shimada S, Yoshimoto-Furuie K, Echizen H: Nomogram for individualizing supplementary iron doses during erythropoietin therapy in haemodialysis patients. J Clin Pharm Ther. 2002;27:111-9. [PMID: 11975695]
Saima S, Furuie K, Yoshimoto H, Fukuda J, Hayashi T, Echizen H: The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. Br J Clin Pharmacol. 2002;53:203-6. [PMID: 11851646]